Clifford Swan Investment Counsel LLC reduced its holdings in Becton Dickinson (NYSE:BDX) by 7.2% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 23,925 shares of the medical instruments supplier’s stock after selling 1,847 shares during the quarter. Clifford Swan Investment Counsel LLC’s holdings in Becton Dickinson were worth $5,185,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also bought and sold shares of the company. MUFG Securities EMEA plc purchased a new position in Becton Dickinson in the 1st quarter valued at approximately $11,919,000. BlackRock Inc. increased its stake in Becton Dickinson by 6.0% in the 4th quarter. BlackRock Inc. now owns 18,811,302 shares of the medical instruments supplier’s stock valued at $4,026,750,000 after purchasing an additional 1,071,288 shares in the last quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH increased its stake in Becton Dickinson by 11.9% in the 1st quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH now owns 39,465 shares of the medical instruments supplier’s stock valued at $8,348,000 after purchasing an additional 4,203 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. increased its stake in Becton Dickinson by 1,392.4% in the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 28,535 shares of the medical instruments supplier’s stock valued at $6,184,000 after purchasing an additional 26,623 shares in the last quarter. Finally, Cigna Investments Inc. New increased its stake in Becton Dickinson by 11.8% in the 4th quarter. Cigna Investments Inc. New now owns 9,741 shares of the medical instruments supplier’s stock valued at $2,085,000 after purchasing an additional 1,025 shares in the last quarter. 84.02% of the stock is owned by institutional investors and hedge funds.
Several research firms have weighed in on BDX. Piper Jaffray reissued an “overweight” rating and set a $260.00 price target (up previously from $223.00) on shares of Becton Dickinson in a research report on Tuesday, February 6th. BMO Capital Markets began coverage on Becton Dickinson in a research report on Monday, March 5th. They set a “market perform” rating and a $249.00 price target for the company. Bank of America reissued a “buy” rating and set a $260.00 price target on shares of Becton Dickinson in a research report on Friday, January 19th. Zacks Investment Research downgraded Becton Dickinson from a “buy” rating to a “hold” rating in a research report on Tuesday, March 6th. Finally, ValuEngine raised Becton Dickinson from a “hold” rating to a “buy” rating in a research report on Wednesday, April 18th. Five analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $241.19.
Becton Dickinson (NYSE:BDX) last announced its quarterly earnings data on Thursday, May 3rd. The medical instruments supplier reported $2.65 EPS for the quarter, beating the Zacks’ consensus estimate of $2.63 by $0.02. The business had revenue of $4.22 billion during the quarter, compared to the consensus estimate of $4.12 billion. Becton Dickinson had a positive return on equity of 14.27% and a negative net margin of 0.46%. The business’s revenue for the quarter was up 42.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.30 earnings per share. research analysts anticipate that Becton Dickinson will post 10.99 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 29th. Stockholders of record on Friday, June 8th will be given a $0.75 dividend. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.34%. The ex-dividend date of this dividend is Thursday, June 7th. Becton Dickinson’s dividend payout ratio is currently 31.65%.
In other news, EVP Nabil Shabshab sold 10,209 shares of Becton Dickinson stock in a transaction on Friday, May 11th. The stock was sold at an average price of $226.10, for a total value of $2,308,254.90. Following the completion of the sale, the executive vice president now owns 12,476 shares of the company’s stock, valued at $2,820,823.60. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Timothy M. Ring sold 176 shares of Becton Dickinson stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $218.27, for a total value of $38,415.52. Following the completion of the sale, the director now directly owns 170,688 shares of the company’s stock, valued at approximately $37,256,069.76. The disclosure for this sale can be found here. In the last ninety days, insiders sold 21,656 shares of company stock valued at $4,892,092. Company insiders own 1.00% of the company’s stock.
About Becton Dickinson
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson (NYSE:BDX).
Receive News & Ratings for Becton Dickinson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and related companies with MarketBeat.com's FREE daily email newsletter.